sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
produc
scare
abstract
appear
china
later
quickli
spread
countri
around
world
although
sinc
disappear
threat
human
health
remain
therefor
studi
prevent
treatment
sar
import
deal
epidem
infecti
diseas
promis
newli
develop
technolog
intervent
sar
may
rna
interfer
endogen
cellular
process
inhibit
gene
express
mediat
sequencespecif
doublestrand
rna
numer
studi
report
therapeut
potenti
rna
interfer
treatment
variou
human
diseas
rang
cancer
infecti
diseas
hiv
hepat
date
studi
inhibit
sarscov
replic
use
small
interf
rna
sirna
conduct
cell
line
vitro
one
studi
use
sirna
inhibit
sarscov
infect
rhesu
macaqu
demonstr
sirna
effect
prophylact
therapeut
advers
effect
anim
challeng
remain
applic
sirna
vivo
sar
prevent
treatment
includ
specif
sirna
effici
deliveri
howev
improv
sirna
design
deliveri
method
rna
interfer
potenti
becom
anoth
major
weapon
combat
danger
infect
due
virus
sarscov
sever
acut
respiratori
syndrom
sar
newli
develop
technolog
intervent
sar
may
rna
interfer
rnai
epidem
high
mortal
rate
sarscov
member
coronaviru
famili
singler
method
treatment
empir
practic
treat
strand
plussens
rna
viru
membran
envelop
typic
influenzalik
symptom
appli
use
ansarscov
genom
approxim
length
encod
tibiot
antivir
agent
ribavirin
oseltamivir
hivproteas
consensu
leader
sequenc
polyprotein
inhibitor
corticosteroid
interferon
normal
human
immuleast
four
major
structur
protein
includ
n
nucleocapsid
noglobulin
prepar
chines
herb
molecular
diagnoss
spike
membran
e
small
envelop
protein
tic
studi
confirm
novel
coronaviru
name
sarscov
four
structur
protein
constitut
viru
particl
n
protein
sarsassoci
coronaviru
respons
disi
virion
rnaassoci
protein
form
long
flexibl
eas
led
search
ration
regimen
treat
helic
nucleocapsid
protein
also
import
viral
rna
infect
includ
gener
vaccin
design
synthesi
protein
glycoprotein
viral
surfac
inhibitor
sarscov
replic
promis
respons
viral
attach
entri
host
cell
protein
necessari
viru
bud
e
protein
viru
cleavag
addit
group
assembl
group
gener
enhanc
function
sirna
duplex
simpl
quick
applic
sarscov
replic
requir
first
partial
duplic
chemic
synthesi
strategi
shown
limit
stabil
genom
translat
genomeencod
protein
product
cost
sirna
lead
first
synthesi
consensu
leader
sequenc
subgenom
polyprotein
leader
sequenc
overcom
limit
chemic
synthesi
sirna
cap
transcript
sarscov
subgenom
plasmidbas
strategi
develop
strategi
dsrna
play
role
translat
structur
protein
bp
hairpin
loop
nine
nucleotid
design
polyprotein
directli
synthes
viral
express
plasmid
control
promot
genom
without
leader
sequenc
protein
includ
papacel
rna
molecul
subject
cleavag
dicer
inlik
cystein
proteas
plpro
cystein
proteas
sirna
sinc
dna
plasmid
easili
econompro
rnadepend
rna
polymeras
rdrp
ical
produc
escherichia
coli
strategi
wide
requir
viral
replic
transcript
step
adopt
character
gene
function
vitro
key
process
viral
replic
potenti
target
therapeut
studi
interrupt
sarscov
replic
sinc
sarscov
repto
address
issu
relat
deliveri
sirna
cell
licat
also
requir
certain
host
protein
gene
host
cell
live
organ
research
use
sever
approach
ininvolv
viral
replic
also
select
target
clude
direct
introduct
chemic
synthes
sirna
ii
employ
liposomeconjug
sirna
plasmid
iii
applic
viral
vector
express
dsrna
small
interf
rna
sirna
applic
hairpin
loop
method
advantag
disadvantag
recent
numer
paper
report
sirna
rna
interfer
endogen
cellular
process
technolog
potent
tool
knockdown
gene
express
inhibit
gene
express
mediat
sequencespecif
therapeut
potenti
treatment
variou
human
diseas
doublestrand
rna
dsrna
phenomenon
first
rang
cancer
infecti
diseas
eg
hiv
hepatiobserv
petunia
flower
later
report
caenorhabd
ti
review
focu
applic
sirna
elegan
dsrna
bp
length
produc
technolog
sar
reader
also
refer
anoth
recent
cleavag
long
rna
duplex
dicer
ribonucleas
iiityp
review
subject
enzym
produc
small
interf
rna
sirna
duplex
activ
process
degrad
mrna
transcript
contain
target
sequenc
process
driven
progress
util
sirna
sirnaenzym
complex
rnainduc
silenc
complex
sever
acut
respiratori
risc
result
inhibit
gene
express
interestingli
syndromeassoci
coronaviru
dsrna
artifici
gener
either
direct
chemic
synthesi
fold
singl
rna
short
dsrna
genom
sequenc
sarscov
determin
hairpin
loop
target
specif
mrna
sequenc
mechan
replic
becam
appar
similar
other
induc
degrad
mrna
therefor
rna
interfer
coronaviru
famili
sirna
target
differ
gene
tool
downregul
gene
express
cultur
sarscov
use
variou
group
inhibit
viru
gene
cell
well
live
organ
express
thereaft
inhibit
replic
viru
see
two
import
issu
must
consid
tabl
initi
report
came
two
group
use
chemith
applic
sirna
downregul
gene
express
cal
synthesi
strategi
first
group
show
two
six
becom
realiti
gener
effect
dsrna
ii
chemic
synthes
sirna
base
sarscov
genom
deliveri
dsrna
target
cell
organ
address
sequenc
result
inhibit
viral
cytopath
effect
cpe
first
issu
research
establish
two
strategi
cell
infect
strain
curfirst
one
chemic
synthes
sirna
method
two
sori
evalu
cpe
transfect
cell
provid
singlestrand
complementari
short
rna
oligonucleotid
evid
sirna
might
effect
inhibit
sarscov
synthes
two
short
oligonucleotid
anneal
replic
second
group
demonstr
three
six
dsrna
test
tube
usual
short
oligonucleotid
sirna
design
target
replicas
sarscov
nucleotid
design
twonucleotid
overhang
facilimoder
effect
wherea
three
less
effect
activ
risc
process
mrna
tive
around
time
zhang
et
al
use
vectorbas
potenti
tool
inhibit
sarscov
replic
even
though
strategi
design
two
differ
sirna
target
se
protein
high
mutat
rate
target
mrna
also
quenc
encod
protein
sarscov
sequenc
report
group
effect
inhibit
chosen
ident
differ
sarscov
sarscov
replic
strain
author
insert
sirna
sequenc
meanwhil
wang
et
al
adopt
similar
strategi
targetvector
promot
express
sirna
cell
ing
viral
rna
polymeras
gene
sarscov
group
group
research
first
demonstr
sirna
use
commerci
avail
vector
psuperretro
design
inhibit
gene
express
viru
replic
vero
cell
six
sirna
research
observ
vero
cell
infect
sarscov
strain
studi
provid
strong
infect
sarscov
strain
two
six
evid
sirna
target
gene
could
employ
sirna
dramat
effect
inhibit
viral
replic
replic
sirna
target
gene
later
ni
et
al
effect
target
rna
polymeras
gene
select
three
potenti
sirna
sequenc
target
confirm
lu
et
al
meng
et
al
leader
sequenc
demonstr
three
sirna
deliv
vector
dramat
inhibit
sarscov
avoid
tediou
work
construct
plasmid
vector
replic
measur
either
plaqu
format
level
test
effect
target
sequenc
zheng
et
al
chemic
synthemrna
protein
n
anoth
group
find
size
sirna
duplex
target
region
throughout
entir
signific
inhibitori
effect
chemic
synthes
sarscov
rna
genom
includ
open
read
frame
sirna
duplex
target
leader
sequenc
li
et
al
ni
sever
key
protein
transfect
sirna
duplex
et
al
separ
demonstr
effect
vectorfet
rhesu
kidney
cell
prior
infect
driven
sirna
target
leader
sequenc
whether
viru
evalu
effici
sirna
inhibit
differ
vectordriven
chemic
syntheof
viral
replic
found
four
sirna
duplex
size
sirna
remain
unclear
potent
inhibitori
effect
sarscov
infect
replic
evalu
intracellular
viral
genom
copi
number
ration
design
effect
sirna
inhibit
sarsvir
titer
cell
cultur
medium
use
quantit
revers
cov
replic
remain
difficult
author
select
transcript
pcr
qrtpcr
cpebas
titrat
respectarget
sequenc
mainli
empir
test
select
target
tive
studi
prolong
prophylact
effect
sirna
sequenc
usual
specif
featur
previou
report
duplex
inhibit
last
least
hour
suggest
eas
select
sirna
target
observ
combin
activ
sirna
duplex
target
sequenc
meng
et
al
adopt
cellbas
assay
screen
differ
region
viral
genom
result
sirna
block
sarscov
gene
express
assay
involv
inhibit
vitro
two
gene
encod
rdrp
envelop
e
protein
respect
author
verifi
publish
sequenc
valid
conveni
rapid
gener
chemitwo
sirna
site
rdrp
gene
two
site
envelop
calli
synthes
sirna
duplex
seem
attract
identifi
gene
assay
provid
specif
strategi
select
effect
cation
target
follow
studi
zheng
et
al
shi
et
sirna
sequenc
al
synthes
sirna
duplex
show
three
effect
inhibit
express
report
gene
carryconsid
viru
may
possibl
escap
sirna
ing
target
sequenc
vero
cell
improv
effectivetarget
viral
mutat
et
al
use
combi
inhibit
group
adopt
strategi
util
mutat
nation
sirna
target
differ
sequenc
author
nucleotid
last
pair
duplex
tt
overhang
reduc
dosag
singl
sirna
duplex
minim
found
modif
duplex
increas
inhibitori
effect
level
test
synergist
effect
combieffect
sarscov
gene
express
observ
connat
differ
duplex
found
combin
firm
mismatch
end
antisens
sirna
sirna
target
two
differ
site
signific
synergisenh
effect
tic
effect
inhibit
sarscov
replic
infect
cell
howev
still
unclear
whether
recent
sirna
inhibit
sarscov
gene
express
synergist
role
could
overcom
problem
viral
escap
replic
report
wu
et
al
describ
three
mutat
studi
observ
synergischem
synthes
sirna
duplex
target
gene
tic
effect
combin
sirna
duplex
high
dose
sequenc
sisaralthough
may
explain
satur
dosag
effect
zhao
et
al
design
sever
sirna
target
sequenc
encod
n
protein
recent
meng
et
current
research
use
chemic
synthesi
al
identifi
sirna
target
e
rdrp
gene
vectorbas
approach
gener
sirna
sarscov
interestingli
two
group
report
effect
target
chemic
synthesi
approach
rapid
easi
leader
sequenc
sarscov
li
et
al
first
identifi
test
rna
stabil
problemat
improv
biostabl
leader
sequenc
mrna
encod
differ
strucelmen
et
al
use
lock
nucleic
acid
lna
approach
tural
protein
base
find
reason
sirna
design
sirna
report
braasch
et
al
lna
could
target
leader
sequenc
effect
inhibit
viral
repliincreas
thermal
stabil
sirna
duplex
without
cation
cell
cultur
system
sinc
would
target
number
deleteri
effect
function
studi
elmen
et
al
protein
simultan
research
group
provid
evid
indic
incorpor
lna
significantli
enhanc
sirna
sirna
target
leader
sequenc
via
promoterbas
stabil
improv
effici
unmodifi
sirna
vector
stronger
effect
inhibit
sarscov
sarscov
inhibit
studi
demonstr
modif
sirna
duplex
could
substanti
improv
activ
sirna
target
differ
sequenc
benefici
therefor
approach
may
enhanc
develop
sirna
effect
sinc
appear
combin
differ
sirna
therapeut
intervent
sarscov
synergist
effect
inhibit
sarscov
replic
base
data
appear
best
approach
would
date
studi
inhibit
sarscov
replicato
use
combin
sirna
maxim
benefit
therefor
tion
use
sirna
conduct
use
cell
line
vitro
suggest
highli
effect
sirna
combin
howev
anim
studi
date
li
et
al
use
report
attempt
use
sirna
inhibit
sarscov
infect
rhesu
macaqu
initi
screen
two
chemion
possibl
advers
effect
vivo
applic
calli
synthes
sirna
select
sirna
base
sirna
may
trigger
host
immun
respons
induct
previou
work
zheng
et
al
research
treat
interferon
howev
sinc
sirna
show
anim
two
sirna
duplex
commonli
use
glucos
advers
effect
possibl
conduct
screen
sirna
solut
prior
infect
sarscov
sequenc
anim
undertak
clinic
studi
anoth
found
monkey
treat
group
show
less
potenti
problem
applic
technolog
vivo
sever
symptom
control
group
report
sirna
overexpress
may
interfer
period
observ
administr
endogen
microrna
process
problem
avoidof
sirna
duplex
treat
monkey
show
averag
ed
lower
deliveri
dose
sirna
express
bodi
temperatur
control
anim
averag
bodi
temperatur
temperatur
chang
deliveri
sirna
correl
chang
lung
histopatholog
intrigu
observ
three
four
anim
studi
refer
review
demonstr
three
sirnatr
group
free
sarscov
potent
inhibitori
effect
sirna
chemic
synthes
oropharyng
swab
specimen
base
measur
sarsand
vector
base
replic
sarscov
cultur
cov
rna
copi
number
indic
sarscov
cell
anim
howev
clinic
applic
particl
releas
anim
lung
dramat
reprophylact
therapeut
context
critic
improv
duce
inject
sirna
duplex
whether
sirna
effici
sirna
deliveri
specif
human
organ
inhibit
sarscov
replic
block
spread
viru
gene
therapi
field
sirna
target
sarscov
hamper
within
lung
remain
determin
howev
studi
barrier
deliveri
work
done
rhesu
macaqu
li
et
clearli
demonstr
sirna
effect
prophylacti
adopt
common
glucos
solut
deliv
calli
therapeut
advers
effect
anim
chemic
synthes
sirna
airway
anim
alstudi
reduct
viru
lung
may
dramat
though
experiment
result
demonstr
dramat
chang
reduc
spread
contact
therebi
effect
approach
sarscov
replic
remain
unclear
much
reduc
spread
viru
patient
caregiv
sirna
duplex
success
deliv
airway
epitheli
cell
anim
long
vivo
transfect
challeng
vivo
applic
sirna
sirna
duplex
maintain
cell
clearli
area
addit
work
need
howev
confid
two
challeng
remain
applic
sirna
vivo
recent
work
gene
target
vaccin
formusar
prevent
treatment
involv
specif
lation
hurdl
insurmount
sirna
effici
deliveri
approach
gene
deliveri
airway
greatli
improv
past
decad
especi
use
viral
vec
tor
helperdepend
adenovir
vector
hdad
target
specif
sirna
import
featur
transduc
almost
airway
epitheli
cell
mice
novel
technolog
therapeut
develop
highli
specif
lesser
degre
rabbit
deliveri
sirna
sirna
select
screen
avoid
potenti
offvir
vector
effect
prophylact
use
sinc
target
side
effect
howev
high
specif
also
express
sirna
viral
vector
expect
last
much
problem
sinc
singl
nucleotid
chang
diminish
effeclong
durat
chemic
synthes
sirna
tive
design
sirna
sinc
mutat
sarstransfect
cell
although
viral
vector
use
deliv
cov
genom
occur
may
result
viral
escap
sirna
sarscov
potenti
advers
effect
inflamsirna
target
et
al
exampl
cao
et
al
shown
interleukin
il
expr
